In one paragraphArticle in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
Sandeep VellankiDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0001-7025-4450 Nathan DeMichaelisDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0009-0002-1914-2423 Catherine LiaoDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Jason E StajichDepartment of Microbiology and Plant Pathology, University of California-Riverside, Riverside, California, USA.ORCID 0000-0002-7591-0020 Robert A CramerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0001-5503-5006 Funding
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3MTranslational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 2018 to 2026
$13.9MEvolution of Aspergillus fumigatus virulenceR01AI130128 · NIAID · DARTMOUTH COLLEGE · PI Robert Andrew Cramer · 2017 to 2026
$4.5MEnvironmental Oxygen Transitions and Aspergillosis Disease ProgressionR01AI146121 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2019 to 2023
$2.6MAcquisition of the NextSeq2000 Sequencing platform to Increase Next Generation Sequencing Throughput While Reducing Costs at DartmouthS10OD030242 · OD · DARTMOUTH COLLEGE · PI KOLLING IV, FRED W · 2021 to 2021
$321kNCI NIH HHS P30 CA023108NIAID NIH HHS R01 AI130128NIAID NIH HHS R01 AI146121NIDDK NIH HHS P30 DK117469NIH HHS S10 OD030242
6 · The paper itselfAbstract
Antibiotic tolerance paves the way for acquired resistance in bacterial pathogens. However, the mechanisms of tolerance and its evolutionary role in acquired resistance in pathogenic fungi, and particularly in filamentous fungi, remain elusive. Here, we identified an
Indexed as
Antifungal AgentsAspergillus fumigatusAzolesDrug Resistance, FungalEpigenesis, GeneticAnimalsBiofilmsDisease Models, AnimalDrug ToleranceFemaleFungal ProteinsInvasive Pulmonary AspergillosisMiceMicrobial Sensitivity TestsVoriconazoleAntifungal AgentsAzolesFungal ProteinsVoriconazoleantifungal drugsAspergillus fumigatusazole resistancedrug tolerance
Identifiers
PMID42294675
PMCPMC13344070
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390